Опыт применения ритуксимаба у пациентов с анкилозирующим спондилитом
https://doi.org/10.14412/1995-4484-2013-1201
Аннотация
Об авторах
М. С. ПротопоповИ. Г. Салихов
С. П. Якупова
С. А. Лапшина
Л. И. Мясоутова
Р. З. Абдракипов
Ш. Ф. Эрдес
Список литературы
1. <div><p>McVeigh C.M., Cairns A.P. Diagnosis and management of ankylosing spondylitis.BMJ 2006;333:581-5.</p><p>Braun J., van der Berg R., Baralikos X. et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.</p><p>Park M.C., Lee S.W., Choi S.T. et al. Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 2007;36:101-6.</p><p>Bal A., Unlu E., Bahar G. et al. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007;26:211-5.</p><p>Gratacos J., Collado A., Filella X. et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33:927-31.</p><p>Lin Q., Gu J.R., Li T.W. et al. Value of the peripheral blood B-cells subsets in patients with ankylosing spondylitis. Chin Med J (Engl) 2009;122:1784-9.</p><p>Dorner T. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol 2006;77(Suppl):3-11.</p><p>Song I.H., Poddubnyy D. New treatment targets in ankylosing spondylitis and other spondyloarthritides. Curr Opin Rheumatol 2011;23:346-51.</p><p>Baeten D., Kruithof E., Breban M. et al. Spondylarthritis in the absence of B lymphocytes. Arthr Rheum 2008;58:730-3.</p><p>Wendling D., Auge B., Streit G. et al. Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis. Joint Bone Spine 2008;75:510-1.</p><p>Mielke F., Schneider-Obermeyer J., Dörner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis 2008;67:1056-7.</p><p>Cohen J.D. Successful treatment of psoriatic arthritis with rituximab. Ann Rheum Dis 2008;67:1647-8.</p><p>Rodriguez-Escalera C., Fernandez-Nebro A. The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. Rheumatology (Oxford) 2008;47:1732-3.</p><p>Nocturne G., Dougados M., Constantin A. Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry. Ann Rheum Dis 2010;69:471-2.</p><p>Song I.H., Heldmann F., Rudwaleit M. et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthr Rheum 2010;62:1290-7.</p><p>Huang Y., Cheng F., Zhang X. et al. Marked reduction of sacroiliac joint inflammation on magnetic resonance imaging in a patient with ankylosing spondylitis after rituximab treatment. J Rheumatol 2011;38:2083-4.</p><p>Van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthr Rheum 1984;27:361-8.</p><p>McLeod C., Bagust A., Boland A. et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technology Assessment 2007;28:11.</p><p>Braun J., Deodhar A., Inman R.D. et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 2011 Oct 19 [Epub. ahead of print].</p><p>Van der Heijde D., Kivitz A., Schiff M.H. et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthr Rheum 2006;54:2136-46.</p><p>Vital E.M., Rawstron A.C., Dass S. et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthr Rheum 2011;63:603-8.</p></div><br />
Рецензия
Для цитирования:
Протопопов М.С., Салихов И.Г., Якупова С.П., Лапшина С.А., Мясоутова Л.И., Абдракипов Р.З., Эрдес Ш.Ф. Опыт применения ритуксимаба у пациентов с анкилозирующим спондилитом. Научно-практическая ревматология. 2013;51(1):48-51. https://doi.org/10.14412/1995-4484-2013-1201
For citation:
Protopopov M.S., Salikhov’ I.G., Yakupova S.P., Lapshina S.A., Myasoutova L.I., Abdrakipov R.Z., Erdes Sh.F. EXPERIENCE WITH RITUXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS. Rheumatology Science and Practice. 2013;51(1):48-51. (In Russ.) https://doi.org/10.14412/1995-4484-2013-1201